Galnon is a low-molecular weight galanin receptor ligand, with affinity towards the three galanin receptors in the micromolar range. Galnon is of interest as a drug candidate due to its stability and ability to pass the blood-brain barrier. Like galanin, galnon has also been shown to affect various physiological functions; however, occasionally galanin and galnon act in opposing ways. Since its introduction in 2002, galnon has been characterized to inhibit seizures, decrease feeding behaviour, diminish physical signs of opiate withdrawal and to alleviate heat-hyperalgesic response to partial sciatic nerve injury. In this review, we will summarize what is known about galnon to date.